Alternative modulation of protein-protein interactions by small molecules

Current Opinion in Biotechnology

Volumn 35, Issue , 2015, Pages 78-85

  Fischer, Gerhard ^a   Rossmann, Maxim ^a   Hyvönen, Marko ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MODULATION; PHYSICOCHEMICAL PROPERTIES;

ALTERNATIVE MODULATION; CLINICAL TRIAL; COMPETITIVE MODE; DRUG DISCOVERY; MODE OF ACTION; PROTEIN-PROTEIN INTERACTIONS; RECENT RESEARCHES; SMALL MOLECULES;

PROTEINS;

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; 4 (4 CHLOROPHENYL) N (4 HYDROXYPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETAMIDE; 4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; 6 (4 CHLOROPHENYL) N ETHYL 8 METHOXY 1 METHYL 4H [1,2,4]TRIAZOLO[4,3 A][1,4]BENZODIAZEPINE 4 ACETAMIDE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; APABETALONE; BI 224436; CALMODULIN; CC 0651; CELL CYCLE PROTEIN 20; CPI 0610; GSK 1324726A; I BET 726; IDASANUTLIN; K RAS PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; METHIONINE; NAVITOCLAX; PREALBUMIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MDM2; PROTEIN P53; RAD51 PROTEIN; SOS PROTEIN; TAFAMIDIS; TEN 010; UNCLASSIFIED DRUG; VENETOCLAX; [2 (4 TERT BUTYL 2 ETHOXYPHENYL) 4,5 BIS(4 CHLOROPHENYL) 4,5 DIHYDRO 4,5 DIMETHYL 1H IMIDAZOL 1 YL][4 [3 (METHYLSULFONYL)PROPYL] 1 PIPERAZINYL]METHANONE; MOLECULAR LIBRARY; PROTEIN BINDING;

ALLOSTERISM; BINDING AFFINITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; ANIMAL; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; HUMAN; METABOLISM; MOLECULAR LIBRARY;

ALLOSTERIC REGULATION; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; PROTEIN BINDING; SMALL MOLECULE LIBRARIES;

EID: 84928645682     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2015.04.006     Document Type: Review

References (54)

1. Koh G.C.K.W., Porras P., Aranda B., Hermjakob H., Orchard S.E. Analyzing protein-protein interaction networks. J Proteome Res 2012, 11:2014-2031.
2. Venkatesan K., Rual J.-F., Vazquez A., Stelzl U., Lemmens I., Hirozane-Kishikawa T., Hao T., Zenkner M., Xin X., Goh K.-I., et al. An empirical framework for binary interactome mapping. Nat Methods 2009, 6:83-90.
3. Raj M., Bullock B.N., Arora P.S. Plucking the high hanging fruit: a systematic approach for targeting protein-protein interactions. Bioorg Med Chem 2013, 21:4051-4057.
4. Giordanetto F., Schäfer A., Ottmann C. Stabilization of protein-protein interactions by small molecules. Drug Discov Today 2014, 8:27-35.
5. Arkin M.R., Tang Y., Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem Biol 2014, 21:1102-1114.
6. Nero T.L., Morton C.J., Holien J.K., Wielens J., Parker M.W. Oncogenic protein interfaces: small molecules, big challenges. Nat Rev Cancer 2014, 14:248-262.
7. Labbé C.M., Laconde G., Kuenemann M.A., Villoutreix B.O., Sperandio O. iPPI-DB: a manually curated and interactive database of small non-peptide inhibitors of protein-protein interactions. Drug Discov Today 2013, 18:958-968.
8. London N., Raveh B., Schueler-Furman O. Druggable protein-protein interactions-from hot spots to hot segments. Curr Opin Chem Biol 2013, 17:952-959.
9. Smith M.C., Gestwicki J.E. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert Rev Mol Med 2012, 14:e16.
10. Boyd S.M., Walse B. Fragment-based drug discovery and protein-protein interactions. Res Reports Biochem 2014, 4:13-26.
11. Thiel P., Kaiser M., Ottmann C. Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery?. Angew Chem Int Ed Engl 2012, 51:2012-2018.
12. Hammoudeh D., Daté M., Yun M. Identification and characterization of an allosteric inhibitory site on dihydropteroate synthase. ACS Chem Biol 2014, 9:1294-1302.
13. Sharma A., Slaughter A., Jena N., Feng L., Kessl J.J., Fadel H.J., Malani N., Male F., Wu L., Poeschla E., et al. A new class of multimerization selective inhibitors of HIV-1 integrase. PLoS Pathog 2014, 10:e1004171.
14. Kessl J.J., Jena N., Koh Y., Taskent-Sezgin H., Slaughter A., Feng L., de Silva S., Wu L., Le Grice S.F.J., Engelman A., et al. Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem 2012, 287:16801-16811.
15. Tsiang M., Jones G.S., Niedziela-Majka A., Kan E., Lansdon E.B., Huang W., Hung M., Samuel D., Novikov N., Xu Y., et al. New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J Biol Chem 2012, 287:21189-21203.
16. Lee C.-H., Lü W., Michel J.C., Goehring A., Du J., Song X., Gouaux E. NMDA receptor structures reveal subunit arrangement and pore architecture. Nature 2014, 511:191-197.
17. Flygare J.a, Beresini M., Budha N., Chan H., Chan I.T., Cheeti S., Cohen F., Deshayes K., Doerner K., Eckhardt S.G., et al. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem 2012, 55:4101-4113.
18. Souers A.J., Leverson J.D., Boghaert E.R., Ackler S.L., Catron N.D., Chen J., Dayton B.D., Ding H., Enschede S.H., Fairbrother W.J., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013, 19:202-208.
19. Xiong H., Pradhan R.S., Nada A., Krivoshik A.P., Holen K.D., Rhodes J.W., Gordon G.B., Humerickhouse R., Awni W.M. Studying navitoclax, a targeted anticancer drug, in healthy volunteers-ethical considerations and risk/benefit assessments and management. Anticancer Res 2014, 34:3739-3746.
20. Wang S., Sun W., Zhao Y., McEachern D., Meaux I., Barrière C., Stuckey J.a, Meagher J.L., Bai L., Liu L., et al. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res 2014, 74:5855-5865.
21. Vu B., Wovkulich P., Pizzolato G., Lovey A., Ding Q., Jiang N., Liu J.-J., Zhao C., Glenn K., Wen Y., et al. Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development. ACS Med Chem Lett 2013, 4:466-469.
22. Ding Q., Zhang Z., Liu J.-J., Jiang N., Zhang J., Ross T.M., Chu X.-J., Bartkovitz D., Podlaski F., Janson C., et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem 2013, 56:5979-5983.
23. Zhao Y., Yu S., Sun W., Liu L., Lu J., McEachern D., Shargary S., Bernard D., Li X., Zhao T., et al. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J Med Chem 2013, 56:5553-5561.
24. Zhong M., Gadek T.R., Bui M., Shen W., Burnier J., Barr K.J., Hanan E.J., Oslob J.D., Yu C.H., Zhu J., et al. Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett 2012, 31:203-206.
25. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
26. Wyce A., Ganji G., Smitheman K.N., Chung C.-W., Korenchuk S., Bai Y., Barbash O., Le B., Craggs P.D., McCabe M.T., et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS One 2013, 8:e72967.
27. You J., Li Q., Wu C., Kim J., Ottinger M., Howley P.M. Regulation of aurora B expression by the bromodomain protein Brd4. Mol Cell Biol 2009, 29:5094-5103.
28. Bailey D., Jahagirdar R., Gordon A., Hafiane A., Campbell S., Chatur S., Wagner G.S., Hansen H.C., Chiacchia F.S., Johansson J., et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol 2010, 55:2580-2589.
29. Chung C.-W., Coste H., White J.H., Mirguet O., Wilde J., Gosmini R.L., Delves C., Magny S.M., Woodward R., Hughes S.A., et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem 2011, 54:3827-3838.
30. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
31. Picaud S., Wells C. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc Natl Acad Sci U S A 2013, 110:19754-19759.
32. Soucek L, Whitfield JR, Sodir NM, Masso D, Serrano E, Karnezis AN, Swigart LB, Evan GI: Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. 2013, doi:10.1101/gad.205542.112.bottlenecks.
33. Yin X., Giap C., Lazo J.S., Prochownik E.V. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 2003, 22:6151-6159.
34. Hammoudeh D.I., Follis A.V., Prochownik E.V., Metallo S.J. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J Am Chem Soc 2009, 131:7390-7401.
35. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007, 7:295-308.
36. Sun Q., Burke J.P., Phan J., Burns M.C., Olejniczak E.T., Waterson A.G., Lee T., Rossanese O.W., Fesik S.W. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl 2012, 51:6140-6143.
37. Maurer T., Garrenton L.S., Oh A., Pitts K., Anderson D.J., Skelton N.J., Fauber B.P., Pan B., Malek S., Stokoe D., et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A 2012, 109:5299-5304.
38. Zimmermann G., Papke B., Ismail S., Vartak N., Chandra A., Hoffmann M., Hahn S.a, Triola G., Wittinghofer A., Bastiaens P.I.H., et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 2013, 497:638-642.
39. Ostrem J.M., Peters U., Sos M.L., Wells J.a, Shokat K.M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013, 503:548-551.
40. Sondermann H., Soisson S.M., Boykevisch S., Yang S.-S., Bar-Sagi D., Kuriyan J. Structural analysis of autoinhibition in the Ras activator Son of sevenless. Cell 2004, 119:393-405.
41. Kastritis P.L., Bonvin A.M.J.J. On the binding affinity of macromolecular interactions: daring to ask why proteins interact. J R Soc Interface 2013, 10. 20120835.
42. Razavi H., Palaninathan S.K., Powers E.T., Wiseman R.L., Purkey H.E., Mohamedmohaideen N.N., Deechongkit S., Chiang K.P., Dendle M.T.a, Sacchettini J.C., et al. Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew Chem Int Ed Engl 2003, 42:2758-2761.
43. Bulawa C.E., Connelly S., Devit M., Wang L., Weigel C., Fleming J.a, Packman J., Powers E.T., Wiseman R.L., Foss T.R., et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A 2012, 109:9629-9634.
44. Penchala S., Connelly S. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A 2013, 110:9992-9997.
45. Huang H., Ceccarelli D.F., Orlicky S., St-Cyr D.J., Ziemba A., Garg P., Plamondon S., Auer M., Sidhu S., Marinier A., et al. E2 enzyme inhibition by stabilization of a low-affinity interface with ubiquitin. Nat Chem Biol 2014, 10:156-163.
46. Merdanovic M., Mönig T., Ehrmann M., Kaiser M. Diversity of allosteric regulation in proteases. ACS Chem Biol 2013, 8:19-26.
47. Maertens G., Cherepanov P., Pluymers W., Busschots K., De Clercq E., Debyser Z., Engelborghs Y. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem 2003, 278:33528-33539.
48. Fischer G., Mutel V., Trube G., Malherbe P., Kew J.N.C., Mohacsi E., Heitz M.P., Kemp J.A., Division P., Basel C. Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J Pharmacol Exp Ther 1997, 283:1285-1292.
49. Duran-Frigola M., Mosca R., Aloy P. Structural systems pharmacology: the role of 3D structures in next-generation drug development. Chem Biol 2013, 20:674-684.
50. Śledź P., Stubbs C.J., Lang S., Yang Y.-Q., McKenzie G.J., Venkitaraman A.R., Hyvönen M., Abell C. From crystal packing to molecular recognition: prediction and discovery of a binding site on the surface of polo-like kinase 1. Angew Chem Int Ed Engl 2011, 50:4003-4006.
51. Silvian L., Enyedy I., Kumaravel G. Inhibitors of protein-protein interactions: new methodologies to tackle this challenge. Drug Discov Today Technol 2013, 10:e509-e515.
52. Villoutreix B.O., Kuenemann M.A., Poyet J.-L., Bruzzoni-Giovanelli H., Labbé C., Lagorce D., Sperandio O., Miteva M.A. Drug-like protein-protein interaction modulators: challenges and opportunities for drug discovery and chemical biology. Mol Inform 2014, 33:414-437.
53. Higueruelo A.P., Schreyer A., Bickerton G.R.J., Pitt W.R., Groom C.R., Blundell T.L. Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. Chem Biol Drug Des 2009, 74:457-467.
54. Higueruelo A.P., Jubb H., Blundell T.L. Protein-protein interactions as druggable targets: recent technological advances. Curr Opin Pharmacol 2013, 13:791-796.